Eli Lilly And Co vs Packaging Corporation of America — how do they compare? Eli Lilly And Co trades at $1,215 (market cap $1.10T), while Packaging Corporation of America trades at $257.2 (market cap $22.70B). The key difference: Eli Lilly And Co is far larger — about 48.5× Packaging Corporation of America's market cap, and Packaging Corporation of America pays the higher dividend (2.36%). Which is the better fit depends on your goals.
| LLY | PKG | |
|---|---|---|
Market Cap | $1.10T | $22.70B |
Sector | Health | Technology |
52-Week High | $1.24K | $256.04 |
52-Week Low | $635.22 | $191.68 |
Enterprise Value | $1.14T | $26.51B |
Dividend Yield | 0.56% | 2.36% |
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,185.71, down 0.59% on the day, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported Q2 2026 revenue growth of 48% to $23 billion, beating estimates, driven by demand for Mounjaro and Zepbound. Valuation ratios like P/E of 39.8 and P/S of 13.34 reflect high growth expectations, while profitability remains robust with a net income margin of 33.53%.
Outlook is positive due to pipeline advancements like retatrutide and raised 2026 guidance, but risks include competitive pressures and regulatory scrutiny. Analysts are bullish with a consensus price target of $1,380, citing sustained double-digit growth and market leadership in weight-loss drugs as key drivers for upside.
Packaging Corporation of America (PKG) trades at $256.04, up 1.3% on the day, with a bullish technical trend supported by moving averages and strong support at $252. The company reported Q2 2026 EPS of $2.35, beating estimates, driven by record corrugated shipments and contributions from the Greif acquisition, though net income margins face pressure from rising costs. A $1.50 dividend for H1-2026 reflects management's confidence, with a consensus price target of $269.33 suggesting modest upside.
Outlook: PKG benefits from robust demand and strategic acquisitions, but cost headwinds and a high P/E of 33.08 pose valuation risks. Analyst sentiment is mixed with 34.6% buy ratings, indicating cautious optimism amid margin compression and economic uncertainties. Key risks include freight and input cost inflation, competitive pricing pressure, and execution of integration synergies.
Trailing returns across standard periods
Latest headlines on both assets
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →